Activist Abortion Academics:
"they are hardly just an ordinary group of concerned doctors."
NRL-ETF Director of Education & Research
National Right to Life
A little less than a year ago, the U.S. Food and Drug Administration (FDA) eased restrictions on the use of the abortion pill RU-486 (miferpistone), reducing required dosages, extending the cutoff time, reducing office visits, and loosening the qualifications for prescribers. It was not enough for the abortion lobby.
On February 23rd, a group of doctors calling themselves the Mifeprex REMS Study Group (mifeprex is the U.S. trade name of mifepristone) published an article in the New England Journal of Medicine titled “Sixteen Years of Overregulation: Time to Unburden.” They called for an end to remaining special restrictions on the drug, asking that it be made available by prescription at retail pharmacies.
As we discuss later in this article, this is not a call of America’s family physicians or pediatricians or even the majority of the country’s Ob-Gyns. This is a publicity ploy of some of America’s top abortion academic activists, trying to pressure the FDA to go even farther than they felt comfortable going just eleven months ago.
Currently, even with the new FDA label, mifepristone is only supposed to be dispensed in clinics, private doctors’ offices, or hospitals by or under the supervision of a “certified healthcare provider” (it used to specify “physician’).
On February 23rd, a group of doctors calling themselves the Mifeprex REMS Study Group (mifeprex is the U.S. trade name of mifepristone) published an article in the New England Journal of Medicine titled “Sixteen Years of Overregulation: Time to Unburden.” They called for an end to remaining special restrictions on the drug, asking that it be made available by prescription at retail pharmacies.
As we discuss later in this article, this is not a call of America’s family physicians or pediatricians or even the majority of the country’s Ob-Gyns. This is a publicity ploy of some of America’s top abortion academic activists, trying to pressure the FDA to go even farther than they felt comfortable going just eleven months ago.
Currently, even with the new FDA label, mifepristone is only supposed to be dispensed in clinics, private doctors’ offices, or hospitals by or under the supervision of a “certified healthcare provider” (it used to specify “physician’).
This certification is minimal. It requires only that the “provider” possess the ability to accurately date the pregnancy (the efficacy of the drugs decreases as gestational age increases), diagnose ectopic pregnancy (the drugs do not work in these circumstances, which could prove fatal), and either have the ability to surgically address complications like severe bleeding or incomplete abortion, or have plans in place for patients to obtain such care from others.
National Right to Life article continues
National Right to Life article continues
No comments:
Post a Comment